Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02905435 · ClinicalTrials.gov registry record · NA

Assessment of Safety and Effectiveness of Biodegradable Temporizing Matrix in the Treatment of Deep Burn Skin Injuries

A NA study of Burns, sponsored by PolyNovo Biomaterials Pty.

Completed
Registry status
NA
Development phase
15
Enrollment target
5
Study locations

NCT02905435 is a NA study of Burns that has completed, run by PolyNovo Biomaterials Pty. The registered enrollment target is 15 participants, below the 83-participant average among 36 other Burns trials with a reported enrollment target (82% lower). The trial reports 5 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02905435, a NA study of Burns, has completed, sponsored by PolyNovo Biomaterials Pty.

COMPLETED
Registry status
NA
Development phase
15 participants
Enrollment target
5
Study locations

Study Summary

This is a multi-center, single arm, traditional feasibility study to allow a preliminary assessment of the safety and effectiveness of a new method of treating skin burns using Biodegradable Temporizing Matrix (BTM).

Conditions Studied

Interventions

  • DEVICE Biodegradable Temporizing Matrix

Study Locations (5)

Arizona

  • Arizona Burn Center at Maricopa Medical Center - Phoenix

California

  • University of California Davis Medical Center - Sacramento

Florida

  • Tampa General Hospital - Tampa

North Carolina

  • Wake Forest University Health Sciences - Winston-Salem

Tennessee

  • University of Tennessee Health Science Center - Memphis

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2016-11-05
Est. Completion 2019-09-18
Phase NA

Sponsor

PolyNovo Biomaterials Pty

3 total trials

What the Registry Record Tells You About NCT02905435

The ClinicalTrials.gov registry entry for NCT02905435 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 83-participant average among 36 other Burns trials with a reported enrollment target (82% lower). The listed sponsor is PolyNovo Biomaterials Pty, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Burns appearing as the primary indexed condition, and to 1 intervention - of which Biodegradable Temporizing Matrix is the first listed.

NCT02905435 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Arizona, California, Florida.

Frequently Asked Questions

What is clinical trial NCT02905435 about?

NCT02905435 is a clinical study titled "Assessment of Safety and Effectiveness of Biodegradable Temporizing Matrix in the Treatment of Deep Burn Skin Injuries". This is a multi-center, single arm, traditional feasibility study to allow a preliminary assessment of the safety and effectiveness of a new method of treating skin burns using Biodegradable Temporizing Matrix (BTM).

What is the current status of trial NCT02905435?

This trial is currently completed. It is a NA study. The enrollment target is 15 participants. The study started on 2016-11-05. Estimated completion is 2019-09-18.

What conditions does trial NCT02905435 study?

This clinical trial studies the following conditions: Burns.

What interventions are being tested in trial NCT02905435?

The interventions under investigation include: Biodegradable Temporizing Matrix (DEVICE).

Who is sponsoring clinical trial NCT02905435?

This trial is sponsored by PolyNovo Biomaterials Pty, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02905435 being conducted?

This trial has 5 study locations across Arizona, California, Florida, North Carolina, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Burns

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.